press release
Monday, March 3, 2025
In the NIH test, the high speed of oral immunotherapy side effects describes the excellence of omalicumab.
According to clinical trials, drugs sold as Xolair have been treated more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of general food allergens. OIT, the most common approach in treating food allergies in the United States, is relevant to gradually consume dose of food allergen to reduce allergic reactions. 36%of the research participants who received the extended course of the O’Malicumab could withstand more than two grams of peanut protein, about eight peanuts and two other food allergens until the end of the treatment period, but only 19%of the participants with multiple it were able to do so. The researchers have led to the discontinuance of treatment due to high proportions of allergic reactions and participants with OITs due to high ratio of allergic reactions and other unstoppable side effects. However, when the participant who stops treatment is excluded from the analysis, the same ratio of each group can withstand at least two grams of three food allergens.
There was a result Post In online supplements that Allergies and clinical immunology journals and presentation The US Allergic Academy, Asthma and Immunology/World Allergic Organization Council held in San Diego on Sunday, March 2, 2025.
Jeanne Marrazzo, NIH’s Allergy and Infectious Disease (NIAID) National Research Institute, said, “People with previously sensitive multi -restaurant allergies have one treatment option to reduce allergic reactions to the right amount of food (oral immunity Therapy). “This study shows that omalicumab is a good alternative because most people can withstand it well. If treatment -related side effects are not a problem, oral immunotherapy remains an effective choice. ”
Omalizumab binds to an allergic -induced antibody called immunoglobulin E from the blood to prevent the allergic reactions from arming. This makes these cells much less sensitive to irritation by all allergens.
Current research is the second stage of A Breakthrough As a result, the O’Malicumab course for 16 weeks has increased the amount of peanuts, wooden nuts, eggs, milk and wheat, which can be consumed by multi -food allergic children without allergic reactions. The next step of this test is designed to compare Omalizumab and OIT for the first time.
In 10 regions of the United States, research teams have registered 177 children aged 1 to 17 and three adults between teenagers and 18 and 55 years old, and all of them are allergic to less than half of the peanuts, similarly to at least two other common foods between milk, eggs, cashews, wheat, hazelnuts or walnuts. After completing the first stage of the exam, 117 individuals entered the second stage of the test.
When I started step 2, all participants received Omalizumab injections for eight weeks. The participants were then randomly divided and placed in one of the two groups. Group A received the O’Malicumab injection and multiple allergen OIT for eight weeks, and Group B received the O’Malicumab injection and placebo for eight weeks. Subsequently, Group A received a placebo and multiple allergen OIT for 44 weeks, and Group B continued to receive O’Malicumab injections and placebo for 44 weeks. Participants or investigators did not know who was the treatment group.
According to the data of previous studies, group A received omalicumab during the early months of OIT, since the pre -treatment by drugs will increase the safety of the OIT significantly and that Omalizumab can be continuously increased for several months in the early years.
During the period of research, 29 out of 59 people in group A A. Therapy: 15 Allergic reactions (some serious) or other unstoppable symptoms of OIT, 14 kinds of disgust or examination of research foods. Participants in Group B had no allergic reactions or other side effects of O’Malicumab, which stopped treatment, but the seven participants of group B had mainly worked due to the burden of participation. Overall, 30 out of 59 of the original 59 (51%) and 51 (88%) out of the original 58 of Group B have completed the treatment.
After the study period, the clinical trial team tested whether the participant who had completed the treatment could eat at least two grams of peanut protein and other two research foods without allergic reactions. 21 or 36%of the original 58 participants in group B can withstand at least 2 grams of all three foods, while only 11 of the original 59 of the group A (OIT-processing group) can do so.. However, when only participants who have completed the treatment, the same ratio of each group can withstand at least 2 grams of three foods.
This results showed that O’Malicumab was originally more effective than OIT when treating multi -base allergies of people with very low resistance to general food allergens. The researchers mainly led to other side effects that led to the interruption of treatment among OIT-treated participants due to the high percentage and other side effects of the allergic reactions, despite being omalicumab before and for several months before treatment.
This test is called omalizumab, called single therapy and adjunct therapy for food allergens and adults. The consortium supported by NIAID for Food Allergy Research (Cofar) is conducted under the leadership of Robert Wood, MD and R. Sharon Chinthrajah, MD Dr. Wood is a Julie and NEIL Reinhard professor of the pediatric clinical research department of Johns Hopkins University of Medicine and is a pediatric clinical research department of Baltomore. Dr. Chinthrajah is an associate professor of medical, pediatric allergies and clinical immunology and co -directors of Sean N. Parker Center and Asthma Research at Stanford University College of Medicine.
Niaid supports funds for the test that is underway with additional financial support and cooperation with Genentech, a member of the Roche Group and Novartis Pharmaceuticals Corporation. The two companies work together to develop and promote the O’Malizumab.
Additional information on the leak test can be found in ClinicalTrials.gov of Study Identifier. NCT03881696.
NIAID develops and supports NIH, the United States and around the world, and develops a better means of preventing, diagnosing and treating these diseases, studying the causes of infectious and immune -mediated diseases. News Release, Fact Sheet and other NIAID related materials NIAID website.
National Institute of Health (NIH) Information:NIH, a US medical research institute, contains 27 institutions and centers and is a component of the Ministry of Health and Welfare. NIH is a major federal agency that conducts and supports basic, clinical and translation medical research and is investigating the cause, treatment and treatment of both general and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Nih… Converting discovery®
reference
Lawood et al. O’Malicumab-The treatment of Dowford Allergies with O’Malicumab compared to the calm multiple allergen OIT. Allergies and clinical immunology journals Doi: 10.1016/J. 2024.12.1022 (2025).
